-
Mashup Score: 0
Our findings suggest increased risks and 1-year burdens of incident dyslipidaemia and incident lipid-lowering medications use in the post-acute phase of COVID-19 infection. Post-acute care for those with COVID-19 should involve attention to dyslipidaemia as a potential post-acute sequela of SARS-CoV-2 infection.
Categories: Endocrinology, Latest HeadlinesTweet
-
Mashup Score: 0Blood lipids after COVID-19 infection - 1 year(s) ago
Atherosclerotic cardiovascular disease incidence is increased both during acute COVID-19 infection and for an indefinite period afterwards.1,2 For this reason it has been recommended that lipid-lowering medication is generally continued throughout the period of active infection and subsequently.2 In this issue of The Lancet Diabetes & Endocrinology, Evan Xu and colleagues3 provide evidence that…
Categories: Endocrinology, Latest HeadlinesTweet-
Also read the Linked Comment: Blood #lipids after #COVID-19 infection https://t.co/ZhJi5QHcyQ #dyslipidaemia #LongCovid #COVID19 #FREE to read
-
-
Mashup Score: 0
Our findings suggest increased risks and 1-year burdens of incident dyslipidaemia and incident lipid-lowering medications use in the post-acute phase of COVID-19 infection. Post-acute care for those with COVID-19 should involve attention to dyslipidaemia as a potential post-acute sequela of SARS-CoV-2 infection.
Categories: Endocrinology, Latest HeadlinesTweet-
New—Risks and burdens of incident #dyslipidaemia in long #COVID: a cohort study https://t.co/cFUB2qfUHE #LongCovid #COVID19 #FREE to read
-
-
Mashup Score: 0Blood lipids after COVID-19 infection - 1 year(s) ago
Atherosclerotic cardiovascular disease incidence is increased both during acute COVID-19 infection and for an indefinite period afterwards.1,2 For this reason it has been recommended that lipid-lowering medication is generally continued throughout the period of active infection and subsequently.2 In this issue of The Lancet Diabetes & Endocrinology, Evan Xu and colleagues3 provide evidence that…
Categories: Endocrinology, Latest HeadlinesTweet-
Paul Durrington comments on: Blood #lipids after #COVID-19 infection https://t.co/ZhJi5QHcyQ #LongCovid #COVID19 #dyslipidaemia #FREE to read
-
-
Mashup Score: 0
Twice-yearly inclisiran provided sustained reductions in LDL cholesterol and PCSK9 concentrations and was well tolerated over 4 years in the extension study. This is the first prospective long-term study to assess repeat hepatic exposure to inclisiran.
Categories: Endocrinology, Latest HeadlinesTweet-
New—Long-term efficacy and safety of #inclisiran in patients with high #cardiovascular risk and elevated LDL #cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial https://t.co/uwxyZyHRYc #dyslipidaemia #OpenAccess
-
-
Mashup Score: 0ORION-3: delivering lipid lowering treatment for longer - 1 year(s) ago
The importance of LDL cholesterol in atherosclerotic cardiovascular disease (ASCVD) is highlighted by countless studies establishing its role in disease causality and clinical trials showing a direct association between lowering LDL cholesterol and reductions in cardiovascular risk. Although treatment guidelines have increasingly emphasised the importance of lipid lowering in cardiovascular…
Categories: Endocrinology, Latest HeadlinesTweet-
Also read the Linked Comment: ORION-3: delivering lipid lowering treatment for longer https://t.co/OxmWqWEoUl #inclisiran #dyslipidaemia
-
-
Mashup Score: 0Metabolic health in the Middle East and north Africa - 2 year(s) ago
The Middle East and north Africa are home to different populations with widely varying cultures, histories, and socioeconomic settings. Hence, their health status, health management, and access to appropriate health care differ accordingly. In this Review, we examine data on the historical and prospective status of metabolic diseases in this region including obesity, diabetes, hypertension,…
Categories: Endocrinology, Latest HeadlinesTweet-
Metabolic health in the Middle East and north Africa https://t.co/HlsF3bhE7e #obesity #diabetes #hypertension #dyslipidaemia #NAFLD #MENA #FREE to read with registration (also FREE) https://t.co/XOUNNyMbj3
-
-
Mashup Score: 0Maximising use of population data on cardiometabolic diseases - 2 year(s) ago
The worldwide burden of adult cardiometabolic diseases such as hypertension, diabetes, obesity, and dyslipidaemia continues its relentless increase. Scaling up the prevention, management, and control of cardiometabolic diseases is cost-effective but requires strong health systems.1 As we have previously argued in this journal,2 building these health systems requires data that is accurate, timely,…
Categories: Endocrinology, Latest HeadlinesTweet-
In the Current Issue: Maximising use of #population #data on #cardiometabolic diseases https://t.co/a4qFwKrLLi #obesity #diabetes #hypertension #dyslipidaemia #globalhealth #NCDs #FREE to read https://t.co/vZSnHfxfSu
-
-
Mashup Score: 3Maximising use of population data on cardiometabolic diseases - 2 year(s) ago
The worldwide burden of adult cardiometabolic diseases such as hypertension, diabetes, obesity, and dyslipidaemia continues its relentless increase. Scaling up the prevention, management, and control of cardiometabolic diseases is cost-effective but requires strong health systems.1 As we have previously argued in this journal,2 building these health systems requires data that is accurate, timely,…
Categories: Endocrinology, Latest HeadlinesTweet-
In the March Issue: Maximising use of population data on #cardiometabolic diseases https://t.co/a4qFwKJn9S #obesity #diabetes #hypertension #dyslipidaemia #NCDs #globalhealth #FREE to read
-
-
Mashup Score: 6
Low HDL cholesterol dyslipidaemia affects about half of people with type 2 diabetes and represents a major independent risk factor for atherosclerotic cardiovascular disease. The “good cholesterol” label was coined decades ago on the basis of a presumed causal role of HDL cholesterol in atherosclerotic cardiovascular disease. However, this view has been challenged by the negative results of…
Categories: Endocrinology, Latest HeadlinesTweet-
Rethinking good #cholesterol: a clinicians' guide to understanding #HDL https://t.co/w1ZVWSnZdx #dyslipidaemia #T2D #ASCVD https://t.co/vV3l3AmSCE
-
Online—Risks and burdens of incident #dyslipidaemia in long #COVID: a cohort study https://t.co/cFUB2qfUHE #LongCovid #COVID19 #FREE to read